Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3.
Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3.
复制标题
DOI:
10.1242/dmm.050144
复制
发表时间:
2023-09-01
影响因子:
4.3
通讯作者:
McLoughlin HS
中科院分区:
文献类型:
--
作者:
Mengel D;Wellik IG;Schuster KH;Jarrah SI;Wacker M;Ashraf NS;Öz G;Synofzik M;Costa MDC;McLoughlin HS
Increased neurofilament light (NfL; NEFL) protein in biofluids is reflective of neurodegeneration and has gained interest as a biomarker across neurodegenerative diseases. In spinocerebellar ataxia type 3 (SCA3), the most common dominantly inherited ataxia, patients exhibit progressive NfL increases in peripheral blood when becoming symptomatic, and NfL remains stably elevated throughout further disease course. However, progressive NfL changes are not yet validated in relevant preclinical SCA3 animal models, hindering its application as a biomarker during therapeutic development. We used ultra-sensitive single-molecule array (Simoa) to measure blood NfL over disease progression in YACQ84 mice, a model of SCA3, assessing relationships with measures of disease severity including age, CAG repeat size and magnetic resonance spectroscopy. YACQ84 mice exhibited plasma NfL increases that were concomitant with ataxia-related motor deficits as well as increased serum NfL, which correlated with previously established neurometabolite abnormalities, two relevant measures of disease in patients with SCA3. Our findings establish the progression of NfL increases in the preclinical YACQ84 mouse, further supporting the utility of blood NfL as a peripheral neurodegeneration biomarker and informing on coinciding timelines of different measures of SCA3 pathogenesis. Summary: Peripheral blood of YACQ84 mice, a model of spinocerebellar ataxia type 3, exhibits increased neuronal-specific NfL, directly associated with disease progression, providing a biomarker to interrogate in preclinical therapeutic studies.
登录
查看更多内容
影响因子:
5.1
作者:
Garcia-Moreno, Hector;Prudencio, Mercedes;Thomas-Black, Gilbert;Solanky, Nita;Jansen-West, Karen R.;Hanna AL-Shaikh, Rana;Heslegrave, Amanda;Zetterberg, Henrik;Santana, Magda M.;Pereira de Almeida, Luis;Vasconcelos-Ferreira, Ana;Januario, Cristina;Infante, Jon;Faber, Jennifer;Klockgether, Thomas;Reetz, Kathrin;Raposo, Mafalda;Ferreira, Ana F.;Lima, Manuela;Schols, Ludger;Synofzik, Matthis;Hubener-Schmid, Jeannette;Puschmann, Andreas;Gorcenco, Sorina;Wszolek, Zbigniew K.;Petrucelli, Leonard;Giunti, Paola
通讯作者:
Giunti, Paola
影响因子:
9.9
作者:
Johnson EB;Byrne LM;Gregory S;Rodrigues FB;Blennow K;Durr A;Leavitt BR;Roos RA;Zetterberg H;Tabrizi SJ;Scahill RI;Wild EJ;TRACK-HD Study Group
通讯作者:
TRACK-HD Study Group
影响因子:
11.2
作者:
Chandrasekaran, Jayashree;Petit, Emilien;Oz, Gulin
通讯作者:
Oz, Gulin
影响因子:
5.1
作者:
Haas E;Incebacak RD;Hentrich T;Huridou C;Schmidt T;Casadei N;Maringer Y;Bahl C;Zimmermann F;Mills JD;Aronica E;Riess O;Schulze-Hentrich JM;Hübener-Schmid J
通讯作者:
Hübener-Schmid J
影响因子:
30.8
作者:
KAWAGUCHI, Y;OKAMOTO, T;KAKIZUKA, A
通讯作者:
KAKIZUKA, A